Cell Free Dna Articles & Analysis: Older
4 articles found
Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty. In the era of precision oncology, it has become increasingly common for patients diagnosed with cancer to undergo tumor sequencing. Identifying the mutations that make up a tumor’s genomic landscape can help guide selection of targeted therapies and inform ...
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers. The ESMO Precision Medicine Working Group (PMWG) first published its recommendations for when to use next-generation sequencing (NGS) in routine practice for patients with metastatic cancers in 20201. At that time, based ...
SEVILLE, Spain--(BUSINESS WIRE)--Universal Diagnostics (UDX), an in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early, announced today that it has started a prospective, multi-center observational study in the US for its investigational advanced adenoma (precursor lesions) and colorectal cancer (CRC) detection blood test. UDX is performing ...
Christian Hense, chief operating officer of Universal Dx, said that the method's workflow begins by collecting about 4ml of plasma from 8ml to 10ml of a patient's blood sample for cell-free DNA (cfDNA) extraction. After Universal Dx performs a series of processing steps to enrich for targets of interest, Hense said that the team then uses ...